In fact, very recently, the first HDAC inhibitor for the treatment of a disease other than cancer, has been approved by the FDA, namely givinostat for the treatment of Duchenne muscular dystrophy [9]. This evidence concerns the gene HDAC9 and Duchenne muscular dystrophy.